Proteasomal degradation of human CYP1B1: Effect of the Asn453Ser polymorphism on the post-translational regulation of CYP1B1 expression

Molecular Pharmacology

Volumn 67, Issue 2, 2005, Pages 435-443

  Bandiera, Silvio ^a   Weidlich, Simone ^a   Harth, Volker ^c   Broede, Peter ^b   Ko, Yun ^d   Friedberg, Thomas ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b LEIBNIZ RESEARCH CENTRE FOR WORKING ENVIRONMENT AND HUMAN FACTORS   (Germany)

^c RUHR UNIVERSITY BOCHUM   (Germany)

^d Johanniter Krankenhaus   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ASPARTIC ACID; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CYCLOHEXIMIDE; CYTOCHROME P450 1B1; CYTOCHROME P450 REDUCTASE; ETHOXYRESORUFIN DEETHYLASE; PROTEASOME; PROTEASOME INHIBITOR; SERINE;

ALLELE; ANIMAL CELL; ARTICLE; CELL LEVEL; CELL STRAIN COS1; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME DEGRADATION; HAPLOTYPE; IMMUNOBLOTTING; IMMUNODETECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN POLYMORPHISM; PROTEIN PROCESSING; PROTEIN STABILITY; UBIQUITINATION;

ALLELES; AMINO ACID SUBSTITUTION; ANIMALS; ASPARAGINE; CERCOPITHECUS AETHIOPS; COS CELLS; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME STABILITY; GENE EXPRESSION REGULATION, ENZYMOLOGIC; POLYMORPHISM, GENETIC; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN PROCESSING, POST-TRANSLATIONAL; SERINE;

EID: 13444288378     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.104.006056     Document Type: Article

References (49)

1. Aklillu E, Oscarson M, Hidestrand M, Leidvik B, Otter C, and Ingelman-Sundberg M (2002) Functional analysis of six different polymorphic CYP1B1 enzyme variants found in an Ethiopian population. Mol Pharmacol 61:586-594.
2. Ariyoshi N, Sawamura Y, and Kamataki T (2001) A novel single nucleotide polymorphism altering stability and activity of CYP2A6. Biochem Biophys Res Commun 281:810-814.
3. Bailey LR, Roodi N, Dupont WD, and Parl FF (1998) Association of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid receptor status in breast cancer. Cancer Res. 58:5038-5041.
4. Black VH, Wang A, Henry M, and Shaw P (1997) Molecular cloning of cDNA for guinea pig CYP1A2 comparison with guinea pig CYP1A1. Arch Biochem Biophys 344:11-17.
5. Buters J, Quintanilla-Martinez L, Schober W, Soballa VJ, Hintermair J, Wolff T, Gonzalez FJ, and Greim H (2003) CYP1B1 determines susceptibility to low doses of 7,12 dimethylbenz(a)anthracene-induced ovarian cancers in mice: correlation of CYP1B1-mediated DNA adducts with carcinogenicity. Carcinogenesis 24:327-334.
6. Correia MA (2003) Hepatic cytochrome P450 degradation: mechanistic diversity of the cellular sanitation brigade. Drug Metab Rev 35:107-143.
7. De Vivo I, Hankinson SE, Li L, Colditz GA, and Hunter DJ (2002) Association of CYP1B1 polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev 11:489-492.
8. Ding S, Deeni YY, Burchell B, Wolf CR, and Friedberg T (2001) Human NADPH-P450 oxidoreductase modulates the level of cytochrome P450 CYP2D6 holoprotein via heme oxygenase-dependent and -independent pathways. Biochem J 356:613-619.
9. Eliasson E, Mkrtchian S, and Ingelman-Sundberg M (1992) Hormone- and substrate-regulated intracellular degradation of cytochrome P450 (2E1) involving MgATP-activated rapid proteolysis in the endoplasmic reticulum membranes. J Biol Chem 267:15765-15769.
10. Friedberg T (2001) Cytochrome P450 polymorphisms as risk factors for steroid hormone-related cancers. Am J Pharmacogenomics 2:83-91.
11. Fritsche E, Bruning T, Jonkmanns C, Ko Y, Bolt HM, and Abel J (1999) Detection of cytochrome P4501B1 Bfr I polymorphism: genotype distribution in healthy German individuals and in patients with colorectal carcinoma. Pharmacogenetics 9:405-408.
12. Goncalves CA and Rodnight R (1993) Electrotransfer of fixed phosphoproteins from pieces of dried gels to small disks of nitrocellulose, nylon or polyvinylidene difluoride. Electrophoresis 14:789-793.
13. Guengerich FP, Chun YJ, Kim D, Gillam EMJ, and Shimada T (2003) Cytochrome P450 1B1: a target for inhibition in anticarcinogenesis strategies. Mutat Res 523-524:173-182.
14. Guengerich FP and Shimada T (1998) Activation of procarcinogens by cytochrome P450 enzymes. Mutat Res 400:201-213.
15. Hanioka N, Tanaka-Kagawa T, Miyata Y, Matsushima E, Makino Y, Ohno A, Yoda R, Jinno H, and Ando M (2003) Functional characterization of three human cytochrome p450 2E1 variants with amino acid substitutions. Xenobiotica 33:575-586.
16. Hanna IH, Dawling S, Roodi N, Guengerich FP, and Parl FF (2000) Cytochrome P4501B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity. Cancer Res 60:3440-3444.
17. Jinno H, Tanaka-Kagawa T, Ohno A, Makino Y, Matsushima E, Hanioka N, and Ando M (2003) Functional characterization of cytochrome P450 2B6 allelic variants. Drug Metab Dispos 31:398-403.
18. Ko Y, Abel J, Harth V, Brode P, Antony C, Donat S, Fischer HP, Ortiz-Pallardo ME, Thier R, Sachinidis A, et al. (2001) Association of CYP1B1 codon 432 mutant allele in head and neck squamous cell cancer is reflected by somatic mutations of p53 in tumor tissue. Cancer Res 61:4398-4404.
19. Korsmeyer KK, Davoll S, Figueiredo-Pereira ME, and Correia MA (1999) Proteolytic degradation of heme-modified hepatic cytochromes P450: a role for phosphorylation, ubiquitination and the 26S proteasome? Arch Biochem Biophys 365:31-44.
20. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (Lond) 227:680-685.
21. Li DN, Seidel A, Pritchard MP, Wolf CR, and Friedberg T (2000) Polymorphisms in P450CYP1B1 affect the conversion of estradiol to the potentially carcinogenic metabolite 4-hydroxyestradiol. Pharmacogenetics 10:343-353.
22. Li YY, Inoue K, and Takei Y (2003) Interrenal steroid 21-hydroxylase in eels: primary structure, progesterone-specific activity and enhanced expression by ACTH. J Mol Endocrinol 31:327-340.
23. Liehr JG and Ricci MJ (1996) 4-Hydroxylation of estrogens as marker of human mammary tumors. Proc Natl Acad Sci USA 93:3294-3296.
24. McFadyen MCE, Breeman S, Payne S, Stirk C, Miller ID, Melvin WT, and Murray GI (1999) Immunohistochemical localization of cytochrome P450 CYP1B1 in breast cancer with monoclonal antibodies specific for CYP1B1. J Histochem Cytochem 47:1457-1464.
25. McGrath M, Hankinson SE, Arbeitman L, Colditz GA, Hunter DJ, and De Vivo I (2004) Cytochrome P450 1B1 and catechol-O-methyltransferase polymorphisms and endometrial cancer susceptibility. Carcinogenesis 25:559-565.
26. McLaughlin L, Burchell B, Pritchard M, Wolf CR, and Friedberg T (1999) Treatment of mammalian cells with the endoplasmic reticulum-proliferator compactin strongly induces recombinant and endogenous xenobiotic metabolizing enzymes. J Cell Sci 112:515-523.
27. McLellan RA, Oscarson M, Hidestrand M, Leidvik B, Jonsson E, Otter C, and Ingelman-Sundberg M (2000) Characterization and functional analysis of two common human cytochrome P450 1B1 variants. Arch Biochem Biophys 378:175-181.
28. McMahon M, Itoh K, Yamamoto M, and Hayes JD (2003) Keap1-dependent proteasomal degradation of transcription factor Nrf2 contributes to the negative regulation of antioxidant response element-driven gene expression. J Biol Chem 278:21592-21600.
29. Meek DW and Milne DM (2000) Analysis of multisite phosphorylation of the p53 tumor-suppressor protein by tryptic phosphopeptide mapping. Methods Mol Biol 99:447-463.
30. Meyer RP, Podvinec M, and Meyer UA (2002) Cytochrome P450 CYP1A1 accumulates in the cytosol of kidney and brain and is activated by heme. Mol Pharmacol 62:1061-1067.
31. Murray GI, Melvin WT, Greenlee WF, and Burke MD (2001) Regulation, function and tissue-specific expression of cytochrome P450 CYP1B1. Annu Rev Pharmacol Toxicol 41:297-316.
32. Murray GI, Taylor MC, McFadyen MC, McKay JA, Greenlee WF, Burke MD, and Melvin WT (1997) Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res 57:3026-3031.
33. Nakamura K, Ariyoshi N, Yokoi T, Ohgiya S, Chida M, Nagashima K, Inoue K, Kodama T, Shimada N, and Kamataki T (2002) CYP2D6.10 present in human liver microsomes shows low catalytic activity and thermal stability. Biochem Biophys Res Commun 293:969-973.
34. Naujokat C and Hoffmann S (2002) Role and function of the 26S proteasome in proliferation and apoptosis. Lab Investig 82:965-980.
35. Roberts BJ (1997) Evidence of proteasome-mediated cytochrome P-450 degradation. J Biol Chem 272:9771-9778.
36. Rylander-Rudqvist T, Wedren S, Granath F, Humphreys K, Ahlberg S, Weiderpass E, Oscarson M, Ingelman-Sundberg M, and Persson I (2003) Cytochrome P450 1B1 gene polymorphisms and postmenopausal breast cancer risk. Carcinogenesis 24:1533-1539.
37. Sasaki M, Tanaka Y, Kaneuchi M, Sakuragi N, and Dahiya R (2003) CYP1B1 gene polymorphisms have higher risk for endometrial cancer and positive correlations with estrogen receptor alpha and estrogen receptor beta expressions. Cancer Res 63:3913-3918.
38. Savas U and Jefcoate CR (1994) Dual regulation of cytochrome P450EF expression via the aryl hydrocarbon receptor and protein stabilization in C3H/10T1/2 cells. Mol Pharmacol 45:1153-1159.
39. Shimada T, Watanabe J, Kawajiri K, Sutter T, Guengerich FP, Gillam EJ, and Inoue K (1999) Catalytic properties of polymorphic human cytochrome P450 1B1 variants. Carcinogenesis 20:1607-1613.
40. Siegel D, Anwar A, Winski SL, Kepa JK, Zolman KL, and Ross D (2001) Rapid polyubiquitination and proteasomal degradation of a mutant form of NAD(P)H: quinone oxidoreductase 1. Mol Pharmacol 59:263-268.
41. Spink DC, Spink BC, Cao JQ, Gierthy JF, Hayes CL, Li Y, and Sutter TR (1997) Induction of cytochrome-P450 1B1 and catechol estrogen metabolism in ACHN human renal adenocarcinoma cells. J Steroid Biochem 62:223-232.
42. Stoilov I, Akarsu AN, Alozie I, Child A, Barsoumhomsy M, Turacli ME, Or M, Lewis RA, Ozdemir N, Brice G, et al. (1998) Sequence analysis and homology modeling suggest that primary congenital glaucoma on 2p21 results from mutations disrupting either the hinge region or the conserved core structures of cytochrome P4501B1. Am J Hum Genet 62:573-584.
43. Szczesna-Skorupa E, Mallah B, and Kemper B (2003) Fluorescence resonance energy transfer analysis of cytochromes P450 2C2 and 2E1 molecular interactions in living cells. J Biol Chem 278:31269-31276.
44. Tanaka Y, Sasaki M, Kaneuchi M, Shiina H, Igawa M, and Dahiya R (2002) Polymorphisms of the CYP1B1 gene have higher risk for prostate cancer. Biochem Biophys Res Commun 296:820-826.
45. Watanabe J, Shimada T, Gillam EM, Ikuta T, Suemasu K, Higashi Y, Gotoh O, and Kawajiri K (2000) Association of CYP1B1 genetic polymorphism with incidence to breast and lung cancer. Pharmacogenetics 10:25-33.
46. Waxman DJ (1999) P450 gene induction by structurally diverse xenochemicals: central role of nuclear receptors CAR, PXR and PPAR. Arch Biochem Biophys 369:11-23.
47. Wickner S, Maurizi MR, and Gottesman S (1999) Posttranslational quality control: folding, refolding and degrading proteins. Science (Wash DC) 286:1888-1893.
48. Wormhoudt LW, Commandeur JNN, and Vermeulen NPE (1999) Genetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione S-transferase and epoxide hydrolase enzymes: relevance to xenobiotic metabolism and toxicity. Crit Rev Toxicol 29:59-124.
49. Zhu BT and Conney AH (1998) Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis 19:1-27.